NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

Fortitech, Inc. company makes nutrient-rich premixes -- chock full of vitamins, minerals, and other ingredients -- that food and beverage makers add to their products to improve their nutritional content. Companies use Fortitech's custom-made nutrient premixes to fortify a variety of foods and other products, including baby formula, cereals, sports drinks, nutrition bars, supplements, snack foods, noodles, and rice. The firm works with its customers to develop blends that target various health conditions or demographic groups; it then makes and distributes the premixes, which come in both liquid and powder form, from facilities located around the world.

Takeda Cambridge (formerly Paradigm Therapeutics) is researching hundreds of potential drug targets in hopes of finding more effective and faster treatments for central nervous system disorders, endocrinology, urology, chronic pain, and metabolic diseases. The genomics-based drug discovery company, which was spun out of the University of Cambridge, uses several research methods based on genetic models and pharmacology to identify drug targets. Subsidiary Takeda Singapore Pte Ltd conducts research in Asia. The company was acquired by Takeda Pharmaceutical in 2007.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

Orchid Cellmark Inc. was founded in 1995 and is headquartered in Princeton, New Jersey. Orchid Cellmark Inc. operates as an international provider of identity DNA testing services for the forensic, immigration, and family relationships markets. The company has laboratories in the United States and the United Kingdom; and offers its services to police forces and other government entities. It also provides non-DNA forensic laboratory services. The company's forensic DNA testing is primarily used to confirm that a suspect committed a particular crime, to exonerate an innocent person, or to establish or maintain databases of individuals convicted of crimes; and family relationship DNA testing is used to establish whether two or more people are genetically related. Its DNA testing is used by individuals and employers in security applications to establish or store a person's genetic profile for identification purposes in the event of an emergency or accident. The company was formerly known as Orchid Biosciences Inc. and changed its name to Orchid Cellmark Inc. in June 2005.

MDS Pharma Services saves drugmakers time and energy when it comes to drug discovery. The company, a subsidiary of MDS, is a provider of contract research and development services for pharmaceutical and biotechnology companies. Through facilities in the Americas, Asia, and Europe, MDS Pharma Services provides its clients with early-stage clinical research and development services, such as consulting, target discovery, lead optimization, regulatory assistance, and Phase I-phase IIa testing. It employs an international network of scientists that serve as testing investigators. MDS Pharma has been put up for sale by parent company MDS.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.